Full Breakdown
Isomorphic Labs Raises $2.1 B to Accelerate AI-Driven Drug Discovery
5/13/2026, 11:00:52 PM
Funding Round Details
On 12 May 2026, Isomorphic Labs announced a $2.1 billion Series B financing. The round was led by Thrive Capital and included existing investors Alphabet, Google Ventures (GV) and CapitalG, together with new participants MGX, Temasek and the UK Sovereign AI Fund. The company did not disclose the post-money valuation.
Company Overview
Founded in 2021 as a spin-out from Google DeepMind, Isomorphic Labs is led by CEO Demis Hassabis. It builds the proprietary Isomorphic Drug Design Engine (IsoDDE), extending AlphaFold’s protein-structure predictions to end-to-end drug design. President Max Jaderberg heads the technical program. The firm operates in London, Cambridge (UK), Massachusetts (USA) and Lausanne (Switzerland).
Data & Statistics
Funding totals about $2.6 billion, including a $600 million Series A in 2025. IsoDDE doubled AlphaFold 3 accuracy on the Runs N’ Poses benchmark and reached 76 % versus 48 % on antibody-antigen interfaces. Open-source projects such as Boltz-2, Chai-1, OpenFold3 and RoseTTAFold All-Atom report comparable benchmark results. Isomorphic runs 17 therapeutic programs in oncology, immunology and cardiovascular disease and partners with Novartis, Eli Lilly and Johnson & Johnson. The team spans AI, engineering, chemistry and clinical science.
Impact
If IsoDDE’s benchmark gains translate to clinical candidates, AI could shorten drug-discovery timelines, reduce R&D costs and reshape pharma business models. The diverse investor base signals confidence that AI platforms may dominate future biotech financing.
Official Statements & Responses
Hassabis said the funding will scale IsoDDE, move from proof-of-concept to commercial deployment, and aim for first AI-designed drugs in human trials by end-2026. Porat called AI in healthcare a profound opportunity and praised progress. Kushner voiced growing confidence in the team’s capacity to usher a new drug-discovery era. Jaderberg noted the engine’s rapid, repeatable identification of viable candidates.
Criticism & Opposition
Open-source researchers argue IsoDDE’s closed code creates a moat that hinders independent verification, leaving the community “left guessing” on replication. No human has yet received an Isomorphic-designed drug, so efficacy remains untested.
Conflicting Reports & Gaps
The trial timeline shifted from late 2025 to end 2026, reflecting uncertainty. Independent validation of IsoDDE’s benchmark improvements beyond internal tests is not publicly available.
Verbatim Quotes
- “Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.” — Demis Hassabis, Founder & CEO, Isomorphic Labs
- “The application of AI in healthcare offers a profound opportunity.” — Ruth Porat, President & CIO, Alphabet & Google
- “Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases,” — Max Jaderberg, President, Isomorphic Labs
- “ Ruth Porat, President and Chief Investment Officer, Alphabet and Google “We are humbled to have the opportunity to continue to support Isomorphic’s mission to solve all disease.” — Joshua Kushner, Founder & CEO, Thrive Capital
What’s Next
Isomorphic will expand AI, engineering and clinical staff, move its 17 pipelines toward Phase I trials in 2026, and deepen ties with Novartis, Eli Lilly and Johnson & Johnson.
